期刊文献+

B淋巴细胞活化与抗体介导的排斥反应 被引量:1

B lymphocyte activation and antibody-mediated rejection
原文传递
导出
摘要 上世纪90年代以前,人们普遍认为移植排斥反应主要由细胞免疫所致.近年来,抗体介导的体液免疫在移植排斥反应过程中的作用重新得到重视,B淋巴细胞则是体液免疫的核心[1].B淋巴细胞活化的过程非常复杂且精确,有众多调控因子参与.目前认为,由B淋巴细胞产生抗体诱导的效应机制包括补体依赖途径和非补体依赖途径的抗体依赖细胞毒性、炎症细胞的募集反应和补体依赖的吞噬作用.最终的病理反应为血小板激活和血栓形成、平滑肌和内皮细胞的病理性增殖以及体液和细胞侵袭损伤内皮细胞进而导致组织损伤.
作者 石炳毅
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2010年第6期321-324,共4页 Chinese Journal of Organ Transplantation
  • 相关文献

参考文献14

  • 1Colvin RB, Smith RN. Antibody-mediated organ allograft rejection. Nat Rev Immunol, 2005,5 (10) : 8(17-817. 被引量:1
  • 2金伯泉.T-B细胞协作研究的重大突破——滤泡辅助性T细胞的发现,一个新的CD4^+效应T细胞亚群[J].细胞与分子免疫学杂志,2009,25(1):1-5. 被引量:32
  • 3Mizoguchi A, Mizoguchi E, Takedatsu H, et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity,2002,16(2) : 219-230. 被引量:1
  • 4Loder F, Mutschler B, Ray R J, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell reeeptor~derived signals. J Exp Med, 1999,190 (1):75 -89. 被引量:1
  • 5Amano M, Baumgarth N, Dick MD, et al. CD1 expression defines subsets of follicular and marginal zone B cells in the spleen:beta 2-microglobulin-dependent and independent forms. J Immunol, 1998,161 (4) : 1710-1717. 被引量:1
  • 6Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol, 2002, 3 (10) :944-950. 被引量:1
  • 7Yanaba K, Bouaziz JD, Matsushita T, et al. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol, 2009,182 ( 12), 7459-7472. 被引量:1
  • 8Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation:new concepts in diagnosis and treatment. Curt Opin Nephrol Hypertens, 2002,11 ( 6 ) : 61}9-618. 被引量:1
  • 9石炳毅,许晓光,蔡明,宋继勇,韩永.体液性排斥反应患者移植物组织C4d沉积和浆细胞聚集性浸润初探[J].中华移植杂志(电子版),2009,3(2):11-14. 被引量:3
  • 10Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by CAd deposits in peritubular capillaries. J Am Soc Nephrol,2001, 12(3) :574-582. 被引量:1

二级参考文献11

  • 1袁双龙,蒋莉,张晓莉,李舒帆,段宏梅,王晓非.原发性干燥综合症患者血清IL-21水平及其临床意义[J].细胞与分子免疫学杂志,2007,23(2):124-126. 被引量:19
  • 2Bouron-Dal Soglio D,,Rougemont AL,Herzog D,et al.An immuno-histochemical evaluation of C4d deposition in pediatric inflammatory liver diseases[].Human Pathology.2008 被引量:1
  • 3Bohmig G A,Regele H,Exner M,et al.C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption[].Journal of the American Society of Nephrology.2001 被引量:1
  • 4Racusen L C,Colvin R B,Solez K,et al.Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection[].American Journal of Transplantation.2003 被引量:1
  • 5Solez K,Colvin RB.Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN‘)[].American Journal of Transplantation.2007 被引量:1
  • 6Imai N,Nishi S,Alchi B.Immunohistochemical evidence of activatedlectin pathway in kidney allografts with peritubular capillary C4d dep-osition[].Nephrology Dialysis Transplantation.2006 被引量:1
  • 7Nickeleit V,Mihatsch MJ.Kidney transplants, antibodies, and rejection: is C4d a magic marker[].Nephrology Dialysis Transplantation.2003 被引量:1
  • 8Feucht HE,Schneeberger H,Hillebrand G et al.Capillary deposition of C4d complement fragment and early renal graft loss[].Kidney International.1993 被引量:1
  • 9Haga H,Egawa H,Fujimoto Y,et al.Acute humoral rejection and C4dimmunostainingin ABObloodtype-incompatibleliver transplan-tation[].Liver Transplantation.2006 被引量:1
  • 10Schmeding M,Dankof A,Krenn V, et al.C4d in acute rejection after liver transplantation--a valuable tool in differential diagnosis to hepatitis C recurrence[].American Journal of Transplantation.2006 被引量:1

共引文献32

同被引文献17

  • 1Glotz D,Antoine C,Julia P,et al.Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins(IVIG).Am J Transplant,2002,(2):758-760. 被引量:1
  • 2Anthony RM,Nimmerjahn F,Ashline DJ,et al.Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fe.Science,2008,320(5874):373-376. 被引量:1
  • 3Vieira CA,Agarwal A,Book BK,et al.Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation:1.Safety,pharmacodynamics,and pharmacokinetics1.Transplantation,2004,77(4):542-548. 被引量:1
  • 4Sidner RA,Book BK,Agarwal A,et al.In vivo human B-cell subset recovery after in vivo depletion with rituximab,antihuman CD20 monoclonal antibody.Hum Antibodies,2004,13(3):55-62. 被引量:1
  • 5Ashley VA,Peng A,Toyoda M,et al.Comparison of desensitization using high-dose(HD) IVIG vs.HD-IVIG + Rituximab in highly-sensitized patients with PRAs > eighty percent(HS).Am J Transplant,2010,10 Suppl 4:S221-222. 被引量:1
  • 6Okamoto M,Koshino K,Nobori S,et al.The excellent shortterm outcomes of ABO-incompatible living kidney transplantation using anti-CD20,CD25 antibody without splenectomy and IVIG.Am J Transplant,2010,10 Suppl 4:S223. 被引量:1
  • 7Habicht A,Broeker V,Richter N,et al.ABO-incompetible kidney transplantation-hannover experience.Am J Transplant,2010,10 Suppl 4:S225. 被引量:1
  • 8Shirakawa H,Ishida H,Shimizu T,et al.The low dose rituximab preconditioning in ABO-incompatible kidney transplantation.:a 3-year follow-up.Am J Transplant,2010,10 Suppl 4:S319. 被引量:1
  • 9Neubert K,Meister S,Moser K,et al.The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupuslike disease from nephritis.Nat Med,2008,14(7):748-755. 被引量:1
  • 10Trivedi HL,Terasaki PI,Feroz A,et al.Abrogation of antiHLA antibodies via proteasome inhibition.Transplantation,2009,87(10):1555-1561. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部